Search Results

You are looking at 1 - 10 of 2,326 items for :

  • Refine by Access: All x
Clear All
Full access

Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven

Background For patients with metastatic esophageal or gastric cancer, palliative systemic therapy is superior to best supportive care (BSC) in terms of survival and can improve quality of life. 1 – 3 After the introduction of chemotherapy

Full access

John A. Glaspy

in gastric cancer cell growth, angiogenesis, and vessel maturation . J Natl Cancer Inst 2004 ; 96 : 946 – 956 . 20 Dunst J Kuhnt T Strauss HG . Anemia in cervical cancers: impact on survival, patterns of relapse, and association with

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

carries a high risk of spreading to regional lymph nodes. Nodal recurrences and distant metastases are common, with limited survival for patients with advanced disease. 5 , 6 Treatment of localized MCC is variable, focusing on wide local excision

Full access

Seyed M. Qaderi, Paul W. Dickman, Johannes H.W. de Wilt, and Rob H.A. Verhoeven

Background Colorectal cancer (CRC) is the third most common cancer in the world. 1 , 2 Survival of patients with CRC has improved significantly because of earlier diagnosis and better treatment of the primary tumor and metastatic disease. 3

Full access

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea, and William A. Wood

) designation, university affiliation, or high patient volume. For example, treatment at an NCICCC has been shown to attenuate survival disparities among young adults with hematologic malignancies, 1 and treatment by a university-based oncologist has been

Full access

Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini

recommendations. No randomized trials exist, and the results of small retrospective case series have led to contradictory conclusions. A study by the Rare Cancer Network showed improved survival with CRT alone compared with surgery/radiotherapy (RT) or surgery

Full access

Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian

-threatening toxicities, such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). 1 – 4 Additionally, there is considerable prognostic variability after CAR T-cell therapy, including length of progression-free survival

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore, and Xiaomei Ma

Background Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm (MPN) characterized by persistently elevated platelet counts. The median age at diagnosis is 68 years 1 and median survival is 19.8 years, which is inferior to that

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

, luminal B, basal-like (triple-negative: ER–/PR–/HER2–), and HER2+/ER–. 1 , 4 These subtypes vary by race and influence survival rate. 5 When physicians prescribe appropriate adjuvant systemic therapies (ASTs) for patients with breast cancer, molecular

Full access

Ju Dong Yang, Michael Luu, Amit G. Singal, Mazen Noureddin, Alexander Kuo, Walid S. Ayoub, Vinay Sundaram, Honore Kotler, Irene K. Kim, Tsuyoshi Todo, Georgios Voidonikolas, Todd V. Brennan, Kambiz Kosari, Andrew S. Klein, Andrew Hendifar, Shelly C. Lu, Nicholas N. Nissen, and Jun Gong

–related factors. 10 Although several studies have reported prognostic factors in large cohorts of patients with HCC, factors specifically associated with survival in patients with T1 HCC remain unknown. With the anticipation of increasing detection of HCC at this